Tue, Oct 22, 2024 page12

• France bristles at painkiller maker’s sale to US fund

  • AFP, PARIS
  • • 
    • 
    • 

  French drugmaker Sanofi’s confirmation yesterday that it plans to sell a controlling stake in its over-the-counter unit to a US investment fund sparked a new political backlash, stoked by fears the deal marks a loss of sovereignty over key medications.

  Paris “must block the sale” using powers to protect strategic sectors, said Manuel Bompard, a senior lawmaker in hard-left France Unbowed (LFI), in an interview with broadcaster TF1.

  Politicians and unions have for weeks criticized Sanofi’s proposed 16-billion-euro (US$17.4 billion) deal with US-based investment fund Clayton Dubilier & Rice (CD&R) for a controlling stake in Opella.

  

  Doliprane paracetamol pills are pictured in Quimper, France, on Wednesday.

  Photo: AFP

  The subsidiary makes household-name drugs, including Doliprane branded paracetamol, whose yellow boxes are a mainstay of almost every French medicine cabinet.

  Under pressure, French Prime Minister Michel Barnier’s minority government said it has secured a 2 percent stake in Orpella for public investment bank Bpifrance and “extremely strong” guarantees against job cuts and offshoring.

  Opella employs more than 11,000 workers and operates in 100 countries.

  Sanofi said it is the third-largest business worldwide in the market for over-the-counter medicines, vitamins and supplements.

  CD&R — which has a battery of existing investments in France — would help build Orpella into a “French-headquartered, global consumer healthcare champion,” the pharma giant said in a statement.

  However, with memories of drug shortages during and since the COVID-19 pandemic still raw for many, critics said the defenses are too weak.

  A small stake “won’t give the French state a say in strategic decisions” at Orpella, said Bompard, whose LFI outfit dominates a left alliance that is the largest opposition bloc against Barnier and pro-business French President Emmanuel Macron.

  His hard-charging LFI colleague Thomas Portes said on X that the government has offered “no guarantees, just words.”

  French Minister of the Economy, Finance and Industry Antoine Armand said that the three-way contract between the CD&R, Sanofi and the government included maintaining production sites, research and development and Orpella’s official headquarters in France, as well as investing at least 70 million euros over five years.

  It covers “keeping up a minimum production volume for Opella’s sensitive products in France,” including Doliprane, digestive medication Lanzor and Aspegic branded aspirin, he added.

  There would be financial penalties for closing French production sites, laying off workers or failing to keep up purchasing from French suppliers.

  That includes Seqens, a company re-establishing production in France of Doliprane’s active ingredient paracetamol.

  The layers of protection have failed to completely convince even some in the government camp.

  Yesterday’s guarantees “do not at all indicate a commitment for the long term, whether on investment, supply or jobs,” said Charles Rodwell, a lawmaker in Macron’s La Republique En Marche party who has closely followed the case.

  He vowed “painstaking” surveillance from parliament of the government’s enforcement of the deal.

  Should ministers fall short, lawmakers would “activate all the tools at parliament’s disposition to block” the sale, he added.

  Macron attempted to quash fears last week, saying that “the government has the instruments needed to protect France” from any unwanted “capital ownership.”

  Emotion over the Opella takeover largely traces back to Doliprane.

  Colorful boxes of the non-opioid analgesic against mild to moderate pain and fever often line entire pharmacy walls.

  The drug comes in many doses — from 100mg for newborn babies to 1,000mg for adults — and in tablet, capsule, suppository and liquid forms.

  It is so ubiquitous that French people call any paracetamol product Doliprane, even when made by a different manufacturer.

  Sanofi, France’s biggest healthcare company and among the world’s top 12, said the planned spinoff is part of a strategy to focus less on over-the-counter medication and more on innovative medicines and vaccines, including for polio, influenza and meningitis.
• Most Popular

  • 1

    MOFA welcomes Rubio’s Taiwan remarks

  • 2

    China seeks to divide Okinawa: report

  • 3

    Cabinet mulls chip aid after Trump threat

  • 4

    Lunar New Year announcement

  • 5

    Regular format resumes on Monday, Feb. 3.